In this work and using kneading, we have compared the encapsulation of progesterone, a lipophilic hormone used in hormone replacement therapy, with β-CD and Nanosponges. The project opens the door to new medical formulations of progesterone, supporting the ball-milling kneading as an exciting way of making complexes.
Our next free webinar, titled “Cyclodextrin formulations: The Journey from the Benchtop to the Patients” brings together experts who will guide us through the milestones of this remarkable journey.
Event Overview: Join us for an illuminating webinar that traces the evolution of cyclodextrin-based drug delivery systems—from laboratory research to real-world patient care. Our esteemed speakers will explore key aspects of this journey, highlighting breakthroughs, challenges, and the promise of cyclodextrins in improving therapeutic outcomes.
Time&Date: September 26., 2024, 3 pm – 5 pm (CEST, Budapest time)
Agenda:
Preparation of Parenteral and Oral Cyclodextrin-Based Formulations and Their Physical CharacterizationSpeaker: Dr. Carmen Popescu (Roquette) – Dr. Popescu will unveil the meticulous process of formulating cyclodextrin-based drugs for parenteral and oral administration. From solubility enhancement to stability studies, discover how cyclodextrins bridge the gap between lab experiments and clinical applications.
Cyclodextrins in Liquid, Transdermal, and Other Non-Traditional FormsSpeaker: Dr. Balazs Kondoros (CarboHyde) – Dr. Kondoros will guide us beyond conventional dosage forms. Explore how cyclodextrins revolutionize liquid formulations, transdermal patches, and other innovative delivery methods. Witness the transition from theoretical concepts to practical solutions.
Hunting for Cyclodextrins: Analytical Assay Methods in Biological FluidsSpeaker: Dr. Tamas Sohajda (Carbohyde) – Dr. Sohajda’s presentation focuses on the detective work involved in studying cyclodextrins within biological matrices. Learn about cutting-edge assay techniques, their role in clinical trials, and the critical insights they provide.
Promising Future for HPBCD in InhalationSpeaker: Dr. Natacha Rocks (Aquilon) – Dr. Rocks will unveil the exciting prospects of hydroxypropyl-β-cyclodextrin (HPBCD) in inhalation therapies. From lung-targeted drug delivery to patient-friendly devices, witness how cyclodextrins are poised to transform respiratory medicine.
Who Should Attend: Researchers, clinicians, pharmaceutical professionals, and anyone curious about the journey of cyclodextrins—from lab discoveries to patient impact.
Don’t miss this opportunity to explore the bridge between science and healing. Register now and join the cyclodextrin revolution!
I would be delighted to hear suggestions for upcoming topics and engage in Q&A, so please feel free to add your impressions in the comments or via email at tamas.sohajda@carbohyde.com. Thank you.
In the coming weeks, we will continue focusing on using cyclodextrins as active ingredients, disease by disease. Stay tuned!
Drug repositioning is a high-priority and feasible strategy in the field of oncology research, where the unmet medical needs are continuously unbalanced. Disulfiram is a potential non-chemotherapeutic, adjuvant anticancer agent. However, the clinical translation is limited by the drug‘s poor bioavailability. Therefore, the molecular encapsulation of disulfiram with cyclodextrins is evaluated to enhance the solubility and stability of the drug.
Throughout the different cancer cell lines‘ characteristics and disulfiram unspecific antitumoral activity, the inhibitory efficacy of the cyclodextrin encapsulated drug on melanoma (IC50 about 100 nM) and on glioblastoma (IC50 about 7000 nM) cell lines differ by a magnitude. This pre-formulation screening experiment serves as proof of concept for using cyclodextrin encapsulation as a platform tool for further drug delivery development in repositioning areas.
Today’s cyclodextrin is a small tribute to a huge contribution to the industrial cyclodextrin applications.
WACKER Chemical Corporation (WCC) established its Eddyville bioprocessing plant in 1999 and recently celebrated its 25th anniversary. The facility manufactures three different high-quality cyclodextrins: Alpha, Beta and Gamma. It is also the world’s sole commercial-scale manufacturer of Alpha and Gamma cyclodextrins.
Guided by WACKER’s global leadership, the Eddyville biotech facility has been at the forefront of cyclodextrin production since it was first built. The cyclodextrin products manufactured by WACKER became known worldwide under the trade names CAVASOL® and CAVAMAX®.
Kristof worked for 5 months in the lab of Jose Manuel Garcia Fernandez under the supervision of Juanma Benito and created various cyclodextrin polymers that we will evaluate for gene and small molecule delivery. 😎 We appreciate the strong support and hospitality of CSIC and look forward to further collaborations.
As Kristof did not take a single photo in the lab, we can only trust he did not only do sightseeing in the wonderful city
CarboHyde CEO Tamas Sohajda recently delivered a compelling presentation at the CPHI North America conference, focusing on innovative applications of cyclodextrins in the pharmaceutical industry. His talk highlighted how these unique cyclic oligosaccharides can enhance drug delivery, improve solubility, and stabilize formulations, offering significant benefits to pharmaceutical development.
Cyclodextrins, known for their ability to form inclusion complexes with various molecules, have been extensively studied for their potential to revolutionize drug formulations. Sohajda’s presentation delved into recent advancements and case studies demonstrating the successful integration of cyclodextrins in new drug delivery systems. These developments promise to improve the efficacy and safety of numerous medications, addressing longstanding challenges in drug formulation and bioavailability.
The talk received considerable attention from industry professionals, underscoring CarboHyde’s leading role in pioneering the use of cyclodextrins for pharmaceutical innovation. Attendees had the opportunity to engage with Sohajda, discussing cyclodextrin research’s practical applications and future directions.
A video of the event is available on CPHI website – after a registration – for those who missed the presentation or wish to revisit the insights shared.
We (Kristóf Felegyi) reported the chemistry work, which was our part, and now look forward to seeing how these building blocks will perform in RNA delivery and eventually in drug formulation. Caitriona O’Driscoll and Ana Francisca Soares presented some of the promising data at the 21st International Cyclodextrin Symposium last week.
We look forward to interesting discussions, progress updates and networking within the GENEGUT consortium 💡
Last week between 10-14 June, the cream of cyclodextrin science gathered in Dunkerque, France to share their knowledge and most recent scientific results during the 21st International Cyclodextrin Symposium.
The conference started with a social tour, visiting nearby sights on the seashore and harbor and spending a wonderful lunch together. We concluded the first-day networking with a welcome party at the Town Hall.
During the event, we could enjoy 81 oral presentations spread across a 3 and half-day scientific fiesta. 166 participants from all around the world (75% Europe, 15% Asia, 10% America) exchanged ideas and initiated collaborations. The most well-represented countries were France, Italy, and Hungary (:P).
During the breaks, we could enjoy bites from French cuisine and discuss further science through the 56 presented posters.
Caitriona O’Driscoll from UCC giving her keynote
The 1st day was topped by a huge Dunkerque beer&cheese carnival, one of the most memorable social events of all time, while the 2nd one with a wonderful Gala dinner at the stunning nearby aquarium.
Bicyclos team at the Dunkerque Carnival
CarboHyde was represented by two members, Daniel Bisericaru and Tamas Sohajda, and presented a talk about the status, future and dilemmas of developing cyclodextrin-based active ingredients. Further collaborations of the company were dominated by sharing the results of two EU-funded projects: GENEGUT & Bicyclos HEurope.
Several awards were presented during the Symposium:
the prestigious Szejtli award went to Sophie Beeren for her groundbreaking work on novel enzymatic methods to create cyclodextrins
the best poster award to Ana Francisca Soares from Genegut on CD-based gene delivery
the best flash presentation to Martina Dragone discussing peptide-CD interactions
the best oral presentation to Clara Testard presenting high-level cyclodextrin synthesis
The conference was concluded by sharing future events where professionals can meet again:
Francesco Trotta will organize a CD Summer school in June, 2025 in Geneva, mainly for students
The next EUROCD will be held in Milano, September, 2025 as shown by Andrea Mele
Keiichi Motoyama invited attendees to Kyoto for the next Asian CD conference to be held in November, 2025.
Today’s cyclodextrin is a fascinating example of how to use the scavenging capabilities of cyclodextrins to develop tools against natural toxins by Alex Fragoso’s team.
Tetrodotoxins (TTXs) are potent marine neurotoxins involved in humans’ poisoning cases after consuming some marine organisms. In this work, five insoluble cyclodextrin polymers with different chemical structures have been investigated as novel clean-up materials for oyster extracts containing TTXs.
The best recoveries have been achieved with βCDP-14-DS2 (∼100 %), which allowed exposing cells to 27-fold higher oyster matrix concentrations and decreased the LOQ down to 46 µg equiv. TTX/kg.
Then, the applicability of this strategy has been demonstrated with oyster extracts from The Netherlands and comparing the results with immunoassay and liquid chromatography-tandem mass spectrometry (LC-MS/MS). This clean-up strategy combined with CBA could be implemented for TTXs detection in monitoring programs to ensure seafood safety.
